[PSMA PET/CT staging in patients with prostate cancer biochemical recurrence]

Argento F, Augustovski F, Colaci C, Alfie V, García Martí S, Bardach A, Ciapponi A, Alcaraz A, Pichon-Riviere A
Record ID 32018004400
Spanish
Original Title: PET/TC con PSMA para la estadificación en pacientes con recurrencia bioquímica de cáncer de próstata
Authors' recommendations: Low-quality evidence suggests that in patients with prostate cancer biochemical recurrence, positron emission tomography/computed tomography scan (PET/CT) with some prostate-specific membrane antigen (PSMA) based radiotracers (68GA-PSMA (Gallium) and 18F-PSMA-1007 (Fluoride)), may result in a lower net benefit, in view of its higher detection rate when compared with PET/CT with other radiotracers. Although the quality of the evidence in improving detection is moderate, evidence regarding changes in therapeutic approach or relevant outcomes for patients is of very poor quality, and therefore the impact this diagnostic improvement might have on them is uncertain. The American Urological Association, as well as the Irish National Cancer Control Program recommend using PET/CT for this population, but they do not recommend a specific radiotracer. On the other hand, the European Association of Nuclear Medicine and the United States Society of Nuclear Medicine and Molecular Imaging recommend using 68GA-PSMA, specially in patients with low prostate-specific antigen (PSA) levels. Argentina’s National Administration of Drugs, Foods and Medical Devices did not approve its use, whereas the European Medical Agency and the United Stated Food and Drug Administration approved it for this population. In Latin America, Uruguay covers its use, while Brazil does not and the rest of the health funders surveyed do not mention it. Public health funders from Australia and the United States cover it, whereas other private health funders do not. There is no information about its cost-effectiveness in Argentina. One study conducted in our country shows that using PSMA radiotracers was cost-effective when compared with non-PSMA radiotracers.
Details
Project Status: Completed
Year Published: 2022
URL for published report: https://www.iecs.org.ar/publicacion/?id=21741
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Prostatic Neoplasms
  • Positron Emission Tomography Computed Tomography
  • Positron-Emission Tomography
  • Radiopharmaceuticals
  • Neoplasm Staging
Contact
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.